A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease
NCT06810960
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The primary purpose of this study is to evaluate safety of LEQEMBI in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in patients treated with LEQEMBI.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Alzheimer's Disease
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Eisai Korea Inc.
- Last updated on ClinicalTrials.gov
- April 21, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New Jersey · 1
- Eisai Trial Site #1 · Nutley, NJ
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.